AARDEX Group

WHOCares -- !>

Introducing ‘Guidance for best
practices for clinical trials’ from the
World Health Organization.

On 24th September 2024, the World Health Organization (WHO) published ‘Guidance for best practices in clinical trials’ which provides the clearest direction yet on what stakeholders working within clinical trials should do to improve outcomes.

The guidance makes several recommendations. Firstly, patient, participant and community engagement are placed centrally in the trial planning and implementation phases. Secondly, trials in underrepresented populations such as children, pregnant women and older adults are better enabled and implemented. The guidance also details how trials should focus design and oversight on the key scientific and ethical considerations that determine whether trials are ethical, efficient and informative

The clearest direction yet that Medication Adherence Solutions should be implemented to ensure optimised clinical trial outcomes.


This guidance responds to requests by the World Health
Assembly to the Director-General in resolution WHA75.8
(2022) on strengthening clinical trials. It aims to provide
the following…

  • High-quality evidence on health interventions to improve research quality and coordination
  • Identify and propose best practices and other measures to strengthen the global clinical trial ecosystem
  • Review existing guidance and develop new guidance as needed on best practices for clinical trials
  • Enhance clinical research efficiency and minimize research waste
  • Provide guidance on sustained clinical trials that are always functional and active for endemic conditions and can pivot in time of emergency or pandemics.

WHO cares. Regulators care. It’s now time you did


‘Automated and digital processes should be encouraged and supported globally to increase clinical trial speed, efficiency and transparency.’

But it isn’t just the WHO that cares. Medication adherence has increasingly become a focus for regulators. Indeed, the In US Food & Drug Administration (FDA) has targeted improvement around dose-selection strategies for oncology drugs through Project Optimus, an initiative of the Oncology Center of Excellence (OCE).

AARDEX is the only mature, robust and proven adherence solution on the market today, one that delivers the clarity, integrity and certainty you need to proceed with complete confidence in the exposure-response.

A library of resources designed to give you the hard evidence you need for your trial.

 

In this section you will helpful resources created to help you understand the WHO guidance, navigate the pathway to better adherence and deliver the hard evidence you need for your trial.

ASK THE EXPERT

Schedule Meeting with our Adherence Expert

Having co-authored over one hundred peer reviewed papers alongside mentoring trial sponsors on medication adherence, our Scientific Lead, Bernard Vrijens, is considered an expert in the field.